IFP Advisors’s TG Therapeutics TGTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $11.5M | Buy |
209,318
+2,780
| +1% | +$114K | 0.21% | 105 |
|
|
2026
Q1 | $6.86M | Buy |
206,538
+9,280
| +5% | +$277K | 0.14% | 162 |
|
|
2025
Q4 | $5.88M | Buy |
197,258
+312
| +0.2% | +$10.2K | 0.13% | 164 |
|
|
2025
Q3 | $7.11M | Buy |
196,946
+6,249
| +3% | +$206K | 0.18% | 113 |
|
|
2025
Q2 | $6.87M | Buy |
190,697
+2,635
| +1% | +$98.1K | 0.2% | 107 |
|
|
2025
Q1 | $7.42M | Buy |
188,062
+9,515
| +5% | +$320K | 0.23% | 91 |
|
|
2024
Q4 | $5.37M | Buy |
178,547
+54,983
| +44% | +$1.58M | 0.18% | 127 |
|
|
2024
Q3 | $2.89M | Buy |
+123,564
| New | +$2.7M | 0.1% | 223 |
|
|
2024
Q2 | – | Sell |
-64
| Closed | -$974 | – | 3342 |
|
|
2024
Q1 | $974 | Buy |
+64
| New | +$1.02K | ﹤0.01% | 2870 |
|
|
2023
Q3 | – | Sell |
-100
| Closed | -$2.48K | – | 3540 |
|
|
2023
Q2 | $2.48K | Sell |
100
-1,000
| -91% | -$25.8K | ﹤0.01% | 2807 |
|
|
2023
Q1 | $14.8K | Sell |
1,100
-26
| -2% | -$395 | ﹤0.01% | 2139 |
|
|
2022
Q4 | $16K | Buy |
1,126
+1,015
| +914% | +$7.37K | ﹤0.01% | 3083 |
|
|
2022
Q3 | $3K | Buy |
111
+9
| +9% | +$59 | ﹤0.01% | 4266 |
|
|
2022
Q2 | $2K | Hold |
102
| – | – | ﹤0.01% | 4193 |
|
|
2022
Q1 | $2K | Buy |
102
+2
| +2% | +$23 | ﹤0.01% | 4191 |
|
|
2021
Q4 | $2K | Hold |
100
| – | – | ﹤0.01% | 2846 |
|
|
2021
Q3 | $3K | Sell |
100
-516
| -84% | -$16K | ﹤0.01% | 2757 |
|
|
2021
Q2 | $25K | Sell |
616
-118
| -16% | -$4.63K | ﹤0.01% | 1836 |
|
|
2021
Q1 | $36K | Buy |
734
+362
| +97% | +$17.4K | ﹤0.01% | 1593 |
|
|
2020
Q4 | $20K | Buy |
372
+321
| +629% | +$10.8K | ﹤0.01% | 1810 |
|
|
2020
Q3 | $2K | Buy |
+51
| New | +$1.17K | ﹤0.01% | 2516 |
|
|
2019
Q1 | – | Sell |
-750
| Closed | -$3K | – | 3342 |
|
|
2018
Q4 | $3K | Sell |
750
-1,450
| -66% | -$7.21K | ﹤0.01% | 3069 |
|
|
2018
Q3 | $12K | Buy |
2,200
+200
| +10% | +$2.29K | ﹤0.01% | 2759 |
|
|
2018
Q2 | $26K | Buy |
2,000
+500
| +33% | +$6.88K | ﹤0.01% | 2322 |
|
|
2018
Q1 | $12K | Hold |
1,500
| – | – | ﹤0.01% | 2687 |
|
|
2017
Q4 | $12K | Sell |
1,500
-450
| -23% | -$3.93K | ﹤0.01% | 2724 |
|
|
2017
Q3 | $23K | Sell |
1,950
-1,900
| -49% | -$21.6K | ﹤0.01% | 2517 |
|
|
2017
Q2 | $39K | Buy |
+3,850
| New | +$43.1K | ﹤0.01% | 2142 |
|
|
2017
Q1 | – | Sell |
-1,000
| Closed | -$5K | – | 4127 |
|
|
2016
Q4 | $5K | Buy |
1,000
+750
| +300% | +$4.4K | ﹤0.01% | 3326 |
|
|
2016
Q3 | $2K | Hold |
250
| – | – | ﹤0.01% | 3620 |
|
|
2016
Q2 | $2K | Buy |
+250
| New | +$2.03K | ﹤0.01% | 3503 |
|
|
2016
Q1 | – | Sell |
-2,250
| Closed | -$27K | – | 3349 |
|
|
2015
Q4 | $27K | Buy |
+2,250
| New | +$28.4K | ﹤0.01% | 1996 |
|
Other funds holding TGTX
SCM
CAM
IFP Advisors's TGTX Position: Q2 2026 in Review
IFP Advisors increased its TG Therapeutics (TGTX) stake by 1.3% in Q2 2026, buying an estimated $114K and bringing the position to 209,318 shares worth $11.5M. The position accounts for 0.21% of the portfolio, ranked #105.
IFP Advisors first reported a position in TGTX in Q4 2015 and has held it in 32 quarters since. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.
- IFP Advisors held 209,318 shares of TG Therapeutics worth $11.5M as of Q2 2026.
- IFP Advisors bought 2,780 TG Therapeutics shares in Q2 2026, an estimated $114K.
- TG Therapeutics made up 0.21% of IFP Advisors's portfolio in Q2 2026, its #105 holding.
- IFP Advisors first reported a position in TG Therapeutics in Q4 2015 and has held it in 32 quarters since.
- 427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.
Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.